Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer
Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, posted on X about recent paper by Syed Arsalan Ahmed Naqvi et al., titled “Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis” published on Science Direct.
Authors: Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, Muhammad Ali Khan, Manal Imran, Kaneez Zahra Rubab Khakwani, Ammad Raina, Muhammad Umair Anjum, Ewan K. Cobran, Jeremy L. Warner, Syed A. Hussain, Parminder Singh, Daniel S. Childs, Sylvan C. Baca, Jacob J. Orme, Joaquin Mateo, Neeraj Agarwal, Silke Gillessen, Mohammad Hassan Murad, Oliver Sartor, Alan H. Bryce.
“Selecting patients with homologous recombination repair mutations for PARP inhibitor therapy in metastatic castration-resistant prostate cancer:
A living meta-analysis of 13 trials (n=4278) highlights:
- Greatest PARPi efficacy in BRCA1/2 alterations
- Potential benefit in PALB2/CDK12
- No clear benefit in ATM/CHEK2.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023